Chu S Y, Bernier R H, Stewart J A, Herrmann K L, Greenspan J R, Henderson A K, Liang A P
Epidemiology Branch, Hawaii State Department of Health, Honolulu.
JAMA. 1988 Jun 3;259(21):3133-6. doi: 10.1001/jama.259.21.3133.
A comparative field trial of three rubella virus vaccines (Cendehill, HPV-77 DE-5, and HPV-77 DK-12) was initiated in 1969 on the islands of Kauai and Hawaii in the state of Hawaii. In 1985, follow-up was reinitiated to assess the long-term durability of vaccine-induced immunity. Enzyme-linked immunosorbent assays of serum specimens from 1290 participants demonstrated seropositive rates of 92.4% and 96.4% at screening levels of 10 (protective level) and 7 (lowest detectable level) IU/mL, respectively. The seropositive rates were not related to reinfection or reimmunizations. These findings indicate that vaccine-induced rubella antibodies are detectable in almost all persons up to 16 years after successful vaccination.
1969年，在夏威夷州的考艾岛和夏威夷岛上开展了三种风疹病毒疫苗（森德希尔疫苗、HPV - 77 DE - 5疫苗和HPV - 77 DK - 12疫苗）的比较性现场试验。1985年，重新开始随访以评估疫苗诱导免疫的长期持久性。对1290名参与者的血清标本进行酶联免疫吸附测定，结果显示，在筛查水平为10（保护水平）和7（最低可检测水平）IU/mL时，血清阳性率分别为92.4%和96.4%。血清阳性率与再次感染或再次免疫无关。这些发现表明，在成功接种疫苗后的16年内，几乎所有人都能检测到疫苗诱导的风疹抗体。
